Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3173677 | 1.00 | LMNA (0.48) | LMNAKDM4ESMN1; SMN2MIFNPC1 | |
| SCHEMBL3581403 | 0.79 | GAA (0.51) | LMNAKDM4ESMN1; SMN2MIFNPC1 | |
| SCHEMBL3581405 | 0.79 | GAA (0.51) | LMNAKDM4ESMN1; SMN2MIFNPC1 | |
| SCHEMBL3031341 | 0.76 | — | — | |
| SCHEMBL3031343 | 0.76 | — | — | |
| SCHEMBL15043322 | 0.76 | — | — | |
| SCHEMBL19133302 | 0.75 | LMNA (0.56) | LMNAKDM4ESMN1; SMN2MIFNPC1 | |
| SCHEMBL535480 | 0.73 | — | — | |
| SCHEMBL16659212 | 0.71 | — | — | |
| SCHEMBL18706184 | 0.71 | KDM4E (0.46) | LMNAKDM4ESMN1; SMN2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816360-B2 | Microsomal triglyceride transfer protein (MTP) inhibitors, used for the treatment of atherosclerosis, pancreatitis, obesity, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and non-insulin dependent diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. | 2010-02-04 | — | — | US | disclosed |
| US-20100004263-A1 | MTP INHIBITING ARYL PIPERIDINES OR PEPERAZINES SUBSTITUTED WITH5-MEMBERED HETEROCYCLES | MEERPOEL LIEVEN | 2010-01-07 | — | — | US | disclosed |
| US-7504400-B2 | for the treatment of atherosclerosis, pancreatitis, obesity, hyper-triglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes; apolipoprotein B secretion inhibitors also for lipid lowering activity; compounds can selectively block MTP at the level of the gut wall in mammals | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-17 | — | — | US | disclosed |
| EP-1751131-B1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-19 | — | — | EP | disclosed |
| EP-1831185-A1 | TRIAZOLONE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS ALPHA-2C ADRENORECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-12 | — | — | EP | disclosed |
| US-20070191383-A1 | Mtp inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| WO-2006067139-A1 | TRIAZOLONE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS ALPHA-2C ADRENORECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, ADRB2, CHRNA5 | LMNA 3405/4885KDM4E 3793/4885SMN1; SMN2 362/4885 |
| US-20070191383-A1 | Mtp inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles | APOB, PNLIP, LPL | LMNA 2586/4885KDM4E 3377/4885SMN1; SMN2 4241/4885 |
| US-20100004263-A1 | MTP INHIBITING ARYL PIPERIDINES OR PEPERAZINES SUBSTITUTED WITH5-MEMBERED HETEROCYCLES | PNLIP, LPL, APOB | LMNA 1815/4885KDM4E 2768/4885SMN1; SMN2 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.